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OBJECTIVE: To determine the cost of treating an inten-
sive care unit (ICU) patient with severe sepsis who expires
while hospitalized at The Johns Hopkins Hospital (JHH),
prior to the introduction of drotrecogin alfa (activated)
for the treatment of severe sepsis. METHOD: The study
utilized a cost-of-illness methodology. Data were col-
lected through retrospective chart review. Patients with
sepsis were identiﬁed based on their discharge summary
in an integrated patient care database at JHH. Patient
selection included those hospitalized between October 1,
2000 and September 30, 2001, in an adult ICU, who
expired prior to hospital discharge. A random sample of
these patients was chosen for chart review. Chart review
identiﬁed patient status based on the PROWESS study
inclusion criteria for the diagnosis of severe sepsis. Cost-
of-illness calculation included direct medical costs (med-
ications, hospital days, and ICU days). The cost to the
hospital was calculated using the cost-to-charge ratio spe-
ciﬁc for JHH. Indirect costs were not included. RESULTS:
A total of 60 patients were included in the study. The
mean total hospital, non-ICU, ICU, and sepsis-related
lengths of stay were 24, 8, 16, and 18 days, respectively.
Patients spent a mean of 67% of hospitalized days in 
the ICU. The mean total hospitalization cost for a 
patient with severe sepsis who expires was approximately
$54,000 and the mean sepsis-related hospitalization cost
for one of these patients was approximately $40,000. The
mean total costs per day (medication costs per day in
parentheses) for the entire hospitalization, non-ICU stay,
ICU stay, and sepsis-related stay were $2270 ($313),
$1512 ($210), $2649 ($364), and $2245 ($339), respec-
tively. CONCLUSION: Sepsis is a condition that has a
signiﬁcant impact on patient mortality and hospital costs.
The results of this study will be used to monitor the effect
of the use of drotrecogin alfa (activated) for the treatment
of severe sepsis at JHH.
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OBJECTIVE: CPCRA-042/CTN-02, was a binational,
randomized, open label trial in patients with advanced
HIV receiving either Nelﬁnivir (NLF) or Ritonavir (RTV).
A pharmacoeconomic (PE) sub-study of consenting 
Canadian participants prospectively captured health
resource utilization (HRU) and Quality of Life (QOL)
data. Our objective was to assess costs, effects and incre-
mental cost-effectiveness of NLF compared to RTV as
Protease Inhibitor therapy. METHOD: The PE sub-study
recruited from 13 Canadian sites. Data collected included
HRU and QOL as measured by a VAS and SF12 every 4
months. Costs were estimated using the St. Paul’s Hospi-
tal (SPH) formulary, SPH Cost Model, and BCMA fee
schedule. Using intent to treat analysis, the annual incre-
mental cost effectiveness ratio (ICER) was calculated.
RESULTS: In the main study, there was no difference in
the time to clinical progression, immunologic or virologic
responses between the two study arms. In PE sub-study,
137 patients were randomized: NLF (n = 71) or RTV 
(n = 66). The median (Q1–Q3) baseline patient age was
38 years (33–44), with median CD4+ count of 36/mm3
(12–70). Total follow-up time was ≥3 years. Preliminary
results show mean (SD) ﬁrst year annual total cost for
NFV patients to be $26,099 (14,800) and $20,475 (7591)
for RTV patients; p < 0.001. QOL scores showed no sig-
niﬁcant difference among groups at one year. The number
of patients switching initially assigned study drug due to
toxicity was lower for the NLF group 19 (27%) vs. 26
(39%) at one year and 8 (12%) vs. 24 (36%) in the ﬁrst
8 months. The annual ICER per switch avoided equaled
$24,071 per patient. CONCLUSION: The overall total
cost and tolerability with assigned therapy were both
higher for NLF. Given equal efﬁcacy and immunologic
response, the choice for one drug over the other as initial
therapy depends on the importance placed on tolerability
of the start-up regimen and potential for the emergence
of drug resistance.
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OBJECTIVES: Even with the advent of new pharma-
cotherapies (e.g., HAART) that minimize inpatient care,
HIV/AIDS patients are sometimes hospitalized for acute
problems. Patients’ responses to speciﬁc aspects of hospi-
talization determine their satisfaction and have implica-
tions for hospitals’ quality improvement efforts. The
objective of this study was to examine ratings of hospi-
talization experiences of HIV/AIDS inpatients and
compare them with ratings of other, non HIV/AIDS inpa-
tients. METHODS: A set of surveys from 78 patients dis-
charged from 32 US hospitals in 2001 was assembled.
Surveys contained 49 items pertaining to aspects of 
hospitalization as well as several patient demographic
items. Surveys had been pre-coded to include diagnostic
information (Diagnosis-Related Group (DRG)) and were
